The Flow has not summarised this story yet — read it at arXiv Machine Learning.
The study presents an explainable multimodal deep‑learning framework that combines a 3D CNN for T1‑weighted MRI with a feedforward network for harmonized clinical and demographic data to diagnose Alzheimer’s disease. Using 6,479 ADNI records and 1,703 OASIS‑3 records, the authors compare various model configurations on three‑way and pairwise diagnostic tasks, finding that performance and explanations vary by task, modality, fusion strategy, and cohort. SHAP and Integrated Gradients consistently highlight the MMSE score as the most influential tabular feature, while CAM‑based explanations differ across model setups and cohorts, indicating that explainability is not a stable property under cohort shift.
arXiv:2607. 07091v1 Announce Type: cross Abstract: In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits.
In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits. Integrating these multimodal observations may improve diagnostic assessment, but naive fusion can degrade performance when MRI is noisy or intermittently unavailable.
arXiv:2606. 11794v1 Announce Type: cross Abstract: Neurodegenerative diseases such as Alzheimer's disease (AD) require accurate and scalable tools for assessing disease severity, yet current clinical staging remains time-intensive and prone to variability.
The paper introduces MCNet, a neural network that assigns a Modality Contribution Score (MCS) to each patient, indicating how much structural MRI versus amyloid PET drives the diagnostic decision for Alzheimer’s disease. Across 327 ADNI-3 participants, MCNet achieved strong three‑class staging (AUC = 0.881) and the MCS showed a clear, statistically significant increase in PET dominance from cognitively normal to AD. The method was validated on an independent OASIS‑3 cohort and compared favorably to SHAP, suggesting it can guide personalized imaging and clinical trial decisions.
arXiv:2610.11394v1 Announce Type: new Abstract: Multimodal Alzheimer's disease (AD) diagnosis benefits from integrating heterogeneous clinical, imaging, genomic, and biomarker evidence, but clinical...